Özet

Methods: A total of 31 patients (3 female, 28 males; mean age 61.0±9.2 years; range 35 to 79 years) with pathologically confirmed diagnosis of NSCLC in Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, 9th Chest Diseases Clinic between January 2007 and October 2010 were included. These patients underwent PET-CT and mediastinoscopy for staging. The mass SUVmax/lymphadenomegaly (lymph node) SUVmax ratios were determined by comparing the primary mass SUVmax with the PET-CT SUVmax value of lymph node with mediastinoscopy-confirmed pathological diagnosis. The reliability of these ratios in detecting metastasis was assessed by dividing the ratios into three groups using the 1.5 and 2.5 cut-off values.

Results: No statistically significant difference was found between patients with positive lymph node results and those with negative results with regards to the mass SUVmax levels (p>0.05). The lymph node SUVmax levels of patients with positive lymph node pathology results were found to be statistically significantly higher than in patients with negative pathology results (p<0.01). The relationship of lymph node positive pathology with mass SUVmax/lymph node SUVmax was found to be statistically significant (p<0.01). The rate of the mass SUVmax/ lymph node SUVmax ratio between 0 and 1.5 in patients with positive pathology results was found to be higher, whereas the rate of mass SUVmax/lymph node SUVmax ratio to be ≥2.5 in patients with negative pathology results was found to be higher.

Conclusion: Our study results showed that the mass SUVmax/lymph node SUVmax ratio viewed on PET-CT is correlated with mediastinal metastasis in patients with NSCLC. We also demonstrated that the false positivity on PET-CT significantly increased in patients with a cut off ratio value was >2.5.

Hilar or mediastinal lymph node involvement is observed in 25% of lung cancer patients, whereas 35-45% show demonstrable distant metastasis by the time of diagnosis.[2] The most commonly encountered controversy concerning the treatment modality of lung cancer and cancer prognosis is the presence or absence of metastasis in the mediastinal lymph nodes (N2-N3 disease).[3-5] As a result, the most important preoperative assessment concerns mediastinal lymph node involvement in patients with a resectable tumor without distant metastasis. This may be performed by radiological, bronchoscopic, or surgical procedures. Clinical assessment of the mediastinal lymph node depends mostly on different imaging methods such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), although these methods are not very reliable in and of themselves.[6]

Our primary objective was to perform the most appropriate staging in order to determine the best treatment modality following the diagnosis of lung cancer. Sometimes the patient’s clinical condition may not permit invasive interventions. The non-invasive PET-CT examination procedure is currently used as an alternative to mediastinoscopic surgical techniques utilized in the evaluation of mediastinal involvement. These techniques are considered the gold standard. However, PET-CT has been accompanied by controversial issues, for example based on the assessment criteria of the maximum standardized uptake values (SUVmax) due to the presence of false positive and false negative conditions.

A SUVmax value of >2.5-3 reinforces the possibility of malignancy in lung and mediastinal lesions. However, there is no definite diagnostic value for the SUVmax value, and it gives false positive results, particularly with granulomatous diseases. Positron emission tomography is not used instead of mediastinoscopy for mediastinal staging due to the 13-22% false positivity reported in many studies.[7-9] The need for mediastinoscopy in the presence of negative PET is still controversial, and a 5-8% false negative result rate has been obtained during mediastinal staging with PET.[10,11]

Many properties of the PET-CT examination procedure, which is used widely with lung cancer, have been investigated by various clinicians in many studies. In this study, we also investigated the reliability of this procedure which is commonly used in our clinic in cancer patients for the detection of mediastinal metastasis by the SUVmax values of a tumor mass and lymph node.

Yöntem

Table 1: Distribution of localization of the mass on PET-CT, the pathology of the mass, and the diagnostic methods of lymph node

Following addmission to our clinic, patients underwent a clinical examination along with an assessment of their biochemistry analyses, and posteroanterior (PA) and lateral chest X-rays were taken. Those who were suspected of having lung cancer were scheduled for thorax CT to obtain a detailed assessment of the lesion, while others underwent fiberoptic bronchoscopy and/ or transthoracic biopsy for histopathological diagnosis. Those who were diagnosed with non-small cell lung cancer (NSCLC) were assessed using PET-CT to detect distant metastasis and mediastinal involvement.

Positron emission tomography-CT images were obtained at three different centers. The SUVmax values of the primary tumor were calculated in the same manner as any abnormal region in the examined area. Mediastinal lymph node involvement stations with a SUVmax value of more than 2.5 were then considered for further evaluation. Lung cancer patients in our clinic who met the following criteria were included in the study:

• Patients who had a pathologically confirmed diagnosis of lung cancer
• Patients who had been subjected to PET-CT for staging and those who had undergone mediastinoscopy.

Patients with a single fasting plasma glucose level of more than 140 mg/dl were not included in the study since high glucose levels reduce image quality. Patients with distant metastasis, those who were deemed to be clinically inoperable, and those who refused surgery were referred for oncological treatment. The pathological results of patients who had undergone a mediastinoscopic examination were obtained, and the patients were then divided into two groups: those with and those without malignancy. Additional imaging techniques and biopsies were performed on patients with symptoms and signs of distant metastasis. The staging of all patients was done according to the tumor (T), node (N), metastasis (M) staging classification system. The SUVmax values for the sizes and histological types of tumors were compared.

Standard cervical mediastinoscopy was performed under conditions where the SUVmax value was more than 2.5 for superior mediastinal lymph nodes as observed on PET. In contrast, thoracoscopy was performed to evaluate involvement of the inferior mediastinal lymph nodes. Systematic lymph node sampling was performed during a thoracotomy. The decision to perform resections during exploration with a thoracotomy was made according to the localization of the mass and lymph node involvement. Mediastinal lymph node dissection was performed if the presence of a mediastinal metastatic lymph node was confirmed by frozen analysis.

The tissue and sections of frozen tissue which were not analyzed during surgery were subjected to standard pathological examination. Sections which were prepared from paraffin blocks were stained with hematoxilen eozin staining.

The Number Cruncher Statistical System (NCSS) 2007 and PASS 2008 statistical software (NCSS, LLC, Kaysville, Utah, USA) programs were used for the statistical analysis of the results obtained during the study. In addition to the definitive statistical methods (mean, standard deviation, frequency) applied for the evaluation of data, Students t-test was used for the comparison of quantitative data between groups for parameters with normal distribution, and the Mann Whitney U-test was used when comparing two groups for parameters without normal distribution., A chi-square test was also employed for comparing qualitative data. A p<0.05 value was considered to be statistically significant.

Bulgular

Table 2: Diagnosis and endobronchial distribution on fiberoptic bronchoscopy

A fiberoptic bronchoscopy (FOB) revealed the diagnosis in 45.2% of the patients, but the diagnosis for the rest of the patients (54.8%) was made by transthoracic needle biopsy and surgery.

The pathology of the mass was identified as squamous cell in 61.3% of the patients, adenocarcinoma in 22.6%, and NSCLC in 16.1% of the patients (Table 3).

Table 3: Age assessment according to pathology

The mean age of patients with positive enlarged mediastinal lymph node pathology was found to be significantly lower than those with negative results (Table 4).

Table 4: The SUVmax of a cancerous mass, the SUVmax of enlarged mediastinal lymph node, mass SUVmax/lymph node SUVmax and the minimum, maximum, mean, standard deviation, and median values of mass sizes

The SUVmax levels of the mass in patients varied between 4 and 41, with a mean of 16.3±9.4 and a median of 16.

The SUVmax levels of enlarged mediastinal lymph node varied between 2.6 and 35, with a mean of 9.1±6.4 and a median of 7.7.

The mass SUVmax/enlarged mediastinal lymph node SUVmax levels varied between 0.36 and 7.34, with a mean of 2.3±1.9 and median of 2.04.

Mass size varied between 1.5 cm and 20 cm, with a mean of 5.8±4.5 cm, and a median of 4 cm (Table 5).

Table 5: Evaluation of the mass SUVmax, lymph node SUVmax, lymph node, mass/lymph node SUVmax and mass size according to the pathology

No statistically significant difference was found between patients with positive mediastinal lymph node pathology results and those whose results were with regard to the SUVmax levels of the mass (p>0.05).

The SUVmax levels of enlarged mediastinal lymph node in patients with positive mediastinal lymph node pathology were significantly higher than those in patients with negative pathology (p<0.01).

The mass SUVmax/mediastinal lymph node SUVmax levels of patients with positive mediastinal lymph node pathology were significantly lower when compared with patients who had negative lymph node pathology results (p<0.01).

No statistically significant difference was found between patients with positive mediastinal lymph node and those with negative results regarding the size of the mass (p>0.05) (Table 6).

Table 6: Evaluation of mass SUVmax/of mediastinal lymph node SUVmax according to pathology

There was a statistically significant relationship between the mediastinal lymph node metastasis and the m ass S UVmax/lymph node S UVmax ratio (p<0.01). The ratio of mass SUVmax/mediastinal lymph node SUVmax between 0 and 1.5 was found to be high in patients with positive lymph node pathology. On the other hand, the ratio of mass SUVmax/lymph node S UVmax ≥ 2.5 w as f ound to be higher in patients with negative lymph node pathology (Table 7).

Table 7: Evaluation of the stage and mass pathology according to the lymph node pathology

No statistically significant difference was found in terms of mediastinal lymph node metastasis with regard to localization of tumor (p>0.05).

Tartışma

The sensitivity and specificity along with the positive and negative predictability of PET-CT with 18F-fluorodeoxyglucose (18F-FDG) for mediastinal evaluation in patients with NSCLC has been shown by many studies to be superior to CT alone.[12-14]

In their meta-analytic comparison published in 1999, Dwamena et al.[15] reported that PET was superior to CT in the detection of lymph node metastasis. In that study, PET demonstrated a sensitivity of 79% (62-97%) and a specificity of 91% (79-99%), whereas CT was found to have a sensitivity of 60% (25-89%) and a specificity of 77% (44-95%). The SUV was calculated as follows: [SUV=activity in the region of interest (mCi/ml)/injected dose (mCi)/body weight (kg)].

In the study conducted by Eroğlu et al.[16] in 2007, it was suggested that mediastinoscopy should not be performed in the presence of non-central tumors and under conditions where the primary tumor is squamous cell carcinoma. In these cases, performing a thoracotomy directly might be a good alternative.

Cerfolio et al.[17] demonstrated an 18F-FDG-PET sensitivity of 71%, a specificity of 77%, a positive predictive value of 44%, and a negative predictive value of 91% for N2 lymph nodes. In the same study, these rates were reported as 43%, 75%, 31%, and 84%, according to CT. A significant difference was found between the two methods with regard to sensitivity and positive predictive value, whereas there was no significant difference with reference to specificity and negative predictive value. The same study also demonstrated that PET was superior to CT for mediastinal staging. However, there was a high rate of false positive results, and it could present false N2 positivity at stations 5#, 6# and 7#. On the other hand, there was no statistically significant difference between the rates of false positivity with regard to lymph node localization (p>0.05).

Cansever et al.[18] demonstrated that 18F-FDG-PET has a sensitivity of 100%, a specificity of 75%, a positive predictive value of 55.5%, a negative predictive value of 100%, and an accuracy rate of 80.9% in the assessment of mediastinal lymph node metastases. The authors suggested that 18F-FDG-PET was a safe method for lung cancer surgery and that it had a good negative predictive value for mediastinal staging.

Gonzalez-Stawinski et al.[19] reported a PET sensitivity of 64%, a specificity of 77%, a positive predictive value of 44%, and a negative predictive value of 88%.

Kernstine et al.[20] reported the sensitivity of PET, CT and MRI as 70%, 65% and 86%, respectively along with a specificity of 86%, 79% and 82%. No significant difference was found between the three methods.

Various studies have demonstrated that the FDG uptake for squamous cell carcinoma was higher than that for adenocarcinoma and bronchoalveolar carcinoma, which could be a reason for false negativity.

Kim et al.[21] demonstrated the FDG uptake of squamous cell carcinomas as 10.8±4.4 and 8.8±3.2 in adenocarcinomas. These results show that sensitivity and specificity of PET for squamous cell carcinomas was higher compared with adenocarcinoma. There was no statistically significant difference in our study between adenocarcinomas and squamous cell carcinomas with regard to false positivity (p>0.05).

The reasons for false positive and false negative have been reported in literature.[19,22,23] Moreover, PET is known to demonstrate false positive results at station 5#, 6# and 7#. As a result, biopsies are required for the confirmation of these stations.[24] No significant difference in false positivity was found in our study regarding the localization of lymph node stations (p>0.05).

In the same study, it was suggested that evaluation of PET together with CT as a suitable non-invasive assessment of mediastinal lymph nodes might reduce the number of invasive interventions. They also suggested that stations suspected of having mediastinal metastasis should be confirmed by a biopsy due to the high rate of false positivity with PET. In addition, invasive mediastinal evaluations should be considered in the patients with other than peripheral T1 tumors due to the high rate of false negativity per patient.[24]

Hiroaki et al.[25] demonstrated in 2007 in their study on 327 patients that the size of the SUVmax value in lung cancer patients with a tumor of more than 3 cm was useful for diagnosis. However, there could be an increase in the diagnostic value of PET-CT when the SUVmax value is combined with the resistive index (RI) value for tumors below 3 cm. In our study, no statistically significant difference was observed between patients with positive lymph node pathology results and those with negative results regarding the size of the mass (p>0.05).

There are many studies which report the use of the SUVmax in the detection of mediastinal lymph nodes and also in the evaluation according to various cutoff values. In the study by Hiroaki et al.[25] a SUVmax value of ≥3.5 was reported with a sensitivity of 80%, a specificity of 99%, and an accuracy of 76%. The RI value was also investigated as an alternative to the SUVmax, and it was calculated as follows:

[RI= (delayed phase SUVmax-early phase SUVmax)/ early phase SUVmax x100)]

Bryan and Cerfolio[26] reported that there was a 24% chance of nodal malignancy under conditions where SUVmax values were between 0-2.5, an 80% chance of malignancy for SUVmax values between 2.6-4.0, and a 96% chance of malignancy for SUVmax values of more than 4.1.

In another study conducted by Bryant et al.[27] a 92% accuracy rate was predicted by this method with a reference SUVmax value of 5.3 for each N2 lymph node station assessed by 18F-FDG-PET. The results of these investigations show that the SUVmax is a predictor for lymph node involvement and that statistically significant SUV differences are observed between malignant and benign lymph nodes.

Standardized uptake values for the primary tumor have been identified by the above studies as independent prognostic factors.[28,29] No fixed SUV value was identified for lymph node metastasis in our study since different PET-CT devices were used at different centers; therefore, they could not be associated with the prognosis. However, the SUVmax values of lymph node in patients in our study with positive pathology results were significantly higher when compared with those with negative pathology results (p<0.01). On the other hand, no statistically significant difference was observed between patients with lymph node metastasis and those without lymph node metastasis (p>0.05).

Furthermore, evaluation of lymph node involvement by non-surgical methods in this study for pathology of the mass in patients who present with NSCLC suggests that better analyses could be performed by using the SUVmax values of lymph nodes in addition to the mass SUVmax/lymph node SUVmax ratio. The rate of false positivity under conditions of lymph node involvement is known to increase independently of the the SUVmax values of lymph node, especially with ratios above 2.5.

The results of our study show that false positivity rate is significantly increased under conditions in which the ratio of tumor SUVmax/lymph node SUVmax was above 2.5 as observed on PET-CT in patients with NSCLC. Our results also demonstrate that the evaluation of the ratio of mass SUVmax/lymph node SUVmax without managing the malignancy of the confirmed mass by using a surgical method may be useful for the detection of whether lymph node involvement was due to metastasis or the result of anthracosis, tuberculosis, and the other granulomatous diseases which are commonly known to lead to false positive results in Turkey.

The S UVmax r atio o f l ymph node t o t he m ass should be considered instead of the SUVmax ratio of lymph node during the evaluation of lymph nodes in the presence of NSCLC. Considering the fact that the SUV value differs between various centers, it is suggested that an evaluation of the mass SUVmax/lymph node SUVmax ratio in addition to the SUVmax value would reduce the rate of false results caused by the difference in SUVmax values between centers. The evaluation of the tumor SUVmax/lymph node SUVmax ratio, patient age, and the SUVmax value of lymph node in addition to the SUVmax value would also help to administer effective treatment by reducing the rate of false positive results through the determination of the most suitable preoperative staging.

Our study also demonstrates that the present use of PET-CT should not take the place of tissue biopsy, but it could help in identifying the localization of the biopsy through proper evaluation of the method.

The use of more standardized parameters in conjunction with the SUVmax value during PET-CT assessment and the reduced cost could increase the future safety of PET-CT and facilitate consideration for its use as a routine supplementary method for diagnosis and staging compared with other imaging methods, such as CT, MRI, and scintigraphy, as well as invasive biopsy methods, such as mediastinoscopy and thoracotomies.

Our study clearly demonstrated that the ratio of mass SUVmax/lymph node SUVmax does not have a certain value at diagnosis, but this study may lead to a new approach in the evaluation of PET-CT results.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

Kaynaklar

1) Özbay B, Uzun K, Yalçınkaya İ. Son üç yıl içinde ilimizde saptadığımız akciğer tümörü olgularının değerlendirilmesi. Tüberküloz ve Toraks Dergisi 1999;47:77-82.

2) Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.

3) Shields TW. Lung cancer: surgical treatment of non-small cell lung cancer. In: Shields TW, Ponn RB, Locicero J, editors. General thoracic surgery. Chapter 99. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2000. p. 1311-43.

4) Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.

5) Johnston MR. Invasive staging of the mediastinum. World J Surg 1993;17:700-4.

6) Shields TW. Lung cancer: diagnosis and staging of lung cancer. In: Shields TW, Ponn RB, Locicero J, editors. General thoracic surgery. Chapter 98, 58. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2000. p. 1297-1311.

7) Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.

8) Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging nonsmall cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.

9) Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.

10) Saunders CA, Dussek JE, O’Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.

11) Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1-92.

12) Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642-8.

13) Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.

14) Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.

15) Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.

16) Eroğlu O, Tanju S, Toker A, Ziyade S, Dilege Ş, Kalaycı G.Küçük hücreli dışı akciğer kanserinde mediastinal lenf nodu evrelemesinde pozitron emisyon tomografisinin yeri. Turk Gogus Kalp Dama 2007;15:133-8.

17) Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 2003;76:861-6.

18) Cansever L, Hacıibrahimoğlu G, Kocatürk C, Sönmezoğlu K, Bedirhan AM. Küçük hücreli dışı akciğer kanseri cerrahisinde 18F-FDG-PET’in evrelemedeki yeri. Toraks Dergisi 2006;7:145-50.

19) Gonzalez-Stawinski GV, Lemaire A, Merchant F, O\'Halloran E, Coleman RE, Harpole DH, D’Amico TA. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1900-5.

20) Kernstine KH, Stanford W, Mullan BF, Rossi NP, Thompson BH, Bushnell DL, et al. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999;68:1022-8.

21) Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998;170:935-9.

22) Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235-42.

23) Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schäfers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003;75:231-5.

24) Yılmazbayhan D. Akciğer tümörlerinde patoloji. In: Yüksel M, Kalaycı NG, editörler. Göğüs cerrahisi. İstanbul: Bilmedya Grup; 2001. s. 221-31.

25) Hiroaki T, Kazuya K, Taeko N, Mituteru Y, Kouichiro K, Takanori M, et al. Evaluation of FDG-PET/CT for lung cancer and lymph nodes metastasis. Journal of Thoracic Oncology 2007;2:587-8.

26) Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-20.

27) Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 2006;82:417-22.

28) Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.

29) Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose- positron emission tomography scan in non-smallcell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.